| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock$25.43
0 (0%)
Market Cap
437.41 M
EPS
1.53
P/E Ratio
17.67 $
Value Trade
74.65 K
SEC Financials
Q1 2026Dilution Risk
Revenue
12.32 M
R&D Expenses
49.00 K
Operating CF
6.12 M
Total Assets
271.86 M
Total Liabilities
158.96 M
Equity
92.88 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
111.10 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
4.01 K
52 Week Range
24.74 - 26.40
% held by Insiders
-
% held by Institutions
-
Enterprise Value
500.31 M
Total Shares
11.91 M
Short %
0.02 %
Float Shares
11.68 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in XOMAO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (XOMAO) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
XOMAO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
XOMAO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
XOMAO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
XOMAO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
XOMAO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-XOMAO
Apr 27, 2026Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator Transaction expands Ligand's royalty portfolio to more than 200 assets and
Ligand Pharmaceuticals has announced its acquisition of XOMA Royalty Corporation for $39.00 per share, totaling approximately $739 million. This deal will expand Ligand's royalty portfolio to over 200 assets, adding seven new commercial products, and is expected to boost Ligand's earnings per share by $1.50 by 2027. The transaction has been unanimously approved by the boards of both companies and is projected to close in the third quarter of 2026. Ligand has raised its financial guidance for 2026 significantly, reflecting confidence in the acquisition's positive outcomes.
Read more →-XOMAO
Mar 18, 2026XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements Portfolio receipts : Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones,
XOMA Royalty Corporation reported strong financial results for 2025, achieving over $50 million in cash receipts, including significant royalties and milestone payments. The company expanded its portfolio by adding 22 assets and completed multiple acquisitions, resulting in increased shareholder value. Despite positive cash flow and a return of capital via share buybacks, XOMA faces legal challenges related to intellectual property. Looking forward, several assets are in advanced clinical stages, presenting potential future growth opportunities.
Read more →-XOMAO
Mar 2, 2026CORPORATE PRESENTATION THE ROYALTY AGGREGATOR NASDAQ COMMON: XOMA FOR BIOTECH NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO COMPANIES Q1 2026 DISCLAIMERS Certain statements in this presentation are forward-looking stat
XOMA Royalty has presented a detailed overview of its strategic direction and financial goals leading into Q1 2026. The company emphasizes its business model as a biotech royalty aggregator, focusing on generating sustainable profitability through royalties. However, it acknowledges potential risks associated with ongoing litigation against Janssen Biotech, which could impact financial outcomes. Investors are cautioned to consider these risks in conjunction with the company's forward-looking statements.
Read more →-XOMAO
Jan 12, 2026XOMA Royalty Announces CFO Transition
XOMA Royalty Corporation announced the departure of CFO Thomas Burns, who has served the company for nearly two decades. Burns played a crucial role in establishing XOMA as a prominent royalty aggregator in the biotech sector. The company has appointed Jeffrey Trigilio, who has a solid background in finance and strategy within the biotech industry, as the new CFO. This leadership change is expected to enhance XOMA's strategic initiatives in capital deployment and portfolio growth.
Read more →-XOMAO
Jan 12, 2026CORPORATE PRESENTATION THE ROYALTY AGGREGATOR NASDAQ COMMON: XOMA FOR BIOTECH NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO COMPANIES JANUARY 2026 DISCLAIMERS Certain statements in this presentation are forward-looking
XOMA Royalty presented a corporate overview detailing its business model and financial performance. The presentation highlighted the potential for monetization through active collaboration with partners and the expected impact of its royalty portfolio on earnings. However, it also included disclaimers about the risks associated with forward-looking statements and the general uncertainties in the biotech sector.
Read more →-XOMAO
Dec 5, 2025XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
XOMA Royalty Corporation has successfully completed its acquisition of Mural Oncology plc, a process which was sanctioned by the Irish High Court and approved by Mural's shareholders. Each Mural shareholder received $2.035 in cash per share as part of the deal. Following the acquisition, Mural’s shares will cease trading on Nasdaq and will be delisted. The transaction marks a significant move for XOMA Royalty in enhancing its portfolio in the biotechnology sector.
Read more →-XOMAO
Nov 12, 2025XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements Business development : Secures royalty economic interests in two early stage partnered assets through
XOMA Royalty Corporation reported its third quarter and year-to-date financial results for 2025, highlighting successful acquisitions, including Turnstone Biologics and HilleVax. The company expects to secure partnerships with LAVA Therapeutics, enhancing its portfolio with early-stage assets. Notably, XOMA achieved $43.9 million in royalties and milestone payments in the first nine months of 2025, demonstrating strong commercial performance. The CEO expressed optimism regarding upcoming clinical data that could further influence XOMA's business direction.
Read more →-XOMAO
Aug 13, 2025XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements Business development : Purchased mezagitamab royalty and milestone rights held by BioInvent Internat
XOMA Royalty Corporation has reported its second quarter and year-to-date financial results for 2025, highlighting a strong performance with $29.6 million in royalties and milestones received. The company has made strategic acquisitions, including the royalty rights for mezagitamab and the merger agreements with Turnstone Biologics and LAVA Therapeutics. These moves are part of XOMA's efforts to diversify its portfolio and enhance shareholder value as it anticipates further cash flow from new commercial opportunities.
Read more →-XOMAO
May 13, 2025XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements Pipeline advancements : The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen s tovorafenib
XOMA Royalty Corporation reported strong financial results for Q1 2025, with cash receipts totaling $18 million and notable developments in its pipeline, including the acceptance of a Marketing Authorization Application for tovorafenib. The company announced its acquisition of an economic interest in Castle Creek Biosciences and the completion of a lucrative royalty financing transaction. Despite high R&D costs and ongoing administrative expenses, XOMA Royalty is optimistic about achieving sustainable cash flow from its royalty income. The CEO emphasized the positive trajectory in their operational metrics and the commitment to enhancing shareholder value.
Read more →-XOMAO
Mar 17, 2025XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential th
XOMA Royalty Corporation reported its fourth quarter and full year 2024 financial results, showcasing a strong expansion of its royalty and milestone portfolio to over 120 assets. Notably, the FDA approved two significant drugs, OJEMDA and MIPLYFFA, which could positively affect revenue streams. While the company achieved $46.3 million in cash receipts, it also faced rising R&D and general expenses, particularly from recent acquisitions. Overall, XOMA maintains a healthy cash reserve and a promising outlook for future growth as it aims to achieve consistent cash flow.
Read more →-XOMAO
Dec 2, 2024XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio Seralutinib becomes XOMA Royalty s seventh Phase 3 royalty asset, further buildi
XOMA Royalty Corporation has acquired Pulmokine Inc. for $20 million, gaining royalty and milestone rights to seralutinib, a Phase 3 candidate for pulmonary arterial hypertension. This acquisition adds to XOMA's portfolio of late-stage royalty assets. The company anticipates seralutinib could potentially target additional cardio-respiratory conditions. Financial returns from this asset will depend on its successful development and market approval, with potential milestone payments of up to $25 million.
Read more →-XOMAO
Nov 7, 2024XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities Zevra s MIPLYFFA (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty s portfolio XOMA Royal
XOMA Royalty Corporation reported its third-quarter financial results for 2024, highlighting significant developments including the FDA approval of Zevra's MIPLYFFA for Niemann-Pick disease Type C, which strengthens its commercial portfolio. The company also completed a royalty monetization agreement with Twist Bioscience to enhance its early-stage asset portfolio. Financially, XOMA Royalty saw a substantial increase in total income from the previous year, although it did record a notable impairment charge linked to one of its royalty agreements. Increased expenses were noted in general and administrative costs, reflecting ongoing business developments.
Read more →-XOMAO
Oct 22, 2024XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience XOMA Royalty has acquired 50 percent of Twist s existing royalty and mileston
XOMA Royalty Corporation has entered into a $15 million agreement with Twist Bioscience Corporation to acquire a 50 percent economic interest in over 60 early-stage programs. This acquisition expands XOMA Royalty's portfolio to include more than 100 assets, ranging from commercial therapeutics to pre-clinical programs, reinforcing its position in the biotechnology royalty sector. The company aims to deliver superior risk-adjusted returns for its shareholders by leveraging this diverse pipeline.
Read more →-XOMAO
Sep 23, 2024Zevra s MIPLYFFA (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) MIPLYFFA is the first therapy approved for use in patients with NPC, a ra
Zevra Therapeutics has received FDA approval for MIPLYFFA (arimoclomol) for treating Niemann-Pick Disease Type C (NPC). This marks the first therapy approved for this rare neurological condition in the U.S., providing new treatment options for patients aged two years and older. XOMA Royalty, which holds a stake in MIPLYFFA, is entitled to receive royalties and potential milestone payments reaching up to $52.6 million. This approval could improve the management of symptoms and slow the progression of this fatal disease.
Read more →-XOMAO
Aug 13, 2024XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolut
XOMA Royalty Corporation reported strong financial results for Q2 2024, with cash receipts of $22.6 million, boosted by milestone payments from Day One Pharmaceuticals and Rezolute. Significant developments included the acquisition of Kinnate Pharmaceuticals, which enhances their royalty portfolio, as well as the approval of OJEMDA for pediatric low-grade glioma. However, the company also faced challenges, including a $9 million impairment charge related to Aronora. Overall, XOMA is positioned for future growth despite some financial setbacks.
Read more →-XOMAO
May 9, 2024XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities Earned $9 million milestone upon U.S. Food and Drug Administration s approval of Day One s OJEMDA (tovorafenib); XOMA is entitled to rece
XOMA Corporation reported its financial results for the first quarter of 2024, highlighting a $9 million milestone received from FDA approval of Day One's OJEMDA. The company has added at least $9.5 million to its capital through the acquisition of Kinnate Pharmaceuticals and expanded its royalty portfolio with new economic interests. Despite a net loss of $8.6 million, XOMA's financial position remains strong with cash and cash equivalents totaling $142.4 million.
Read more →-XOMAO
Apr 30, 2024XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO (clindamycin phosphate) Vaginal Gel 2% Organon, a global women s healthcare company, initiated XACIA
XOMA Corporation has acquired economic interests in three women's health assets, including XACIATO, a vaginal gel approved by the FDA for bacterial vaginosis. The acquisition also includes Ovaprene, a hormone-free contraceptive, and Sildenafil Cream, an investigational treatment for female sexual arousal disorder. This transaction is valued at $22 million and adds to XOMA's portfolio of royalty and milestone interests. Each asset presents a meaningful opportunity for growth within the under-represented women's health category.
Read more →-XOMAO
Apr 25, 2024XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One s OJEMDA TM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) XOMA is entitled to a mid-single digit roy
XOMA Corporation has secured a $9 million milestone payment following the FDA's accelerated approval of OJEMDA (tovorafenib) for treating relapsed or refractory BRAF-altered pediatric low-grade glioma. This treatment is notable as it is the first FDA-approved type II RAF inhibitor specifically for this patient group. XOMA is entitled to mid-single digit royalties on global sales of OJEMDA, highlighting the potential financial impact on the company. CEO Owen Hughes remarked on the significance of this advancement for affected children.
Read more →-XOMAO
Mar 8, 2024XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value Raised up to $140 million of non-dilutive non-recourse capital through a roya
XOMA Corporation reported its fourth quarter and full year 2023 financial results, highlighting several significant developments, including a $140 million royalty-backed loan to support growth. The company has added to its portfolio with the acquisition of DSUVIA, alongside receiving substantial cash payments from royalties and milestones. Despite recording a net loss of $40.8 million for the year, XOMA ended 2023 with a strong cash position, bolstered by upcoming regulatory events and plans for stock repurchases.
Read more →-XOMAO
Feb 16, 2024XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its bala
XOMA Corporation has announced an agreement to acquire Kinnate Biopharma for a cash price ranging from $2.3352 to $2.5879 per share, plus a contingent value right. This acquisition aims to enhance XOMA's cash reserves and add several early-stage oncology programs to its portfolio. Kinnate's Board of Directors has unanimously approved the agreement, expressing confidence in the merger's benefits for shareholders. The tender offer is expected to commence on March 4, 2024, with a targeted completion date in April 2024, pending necessary conditions and shareholder support.
Read more →-XOMAO
Jan 2, 2024XOMA Announces Stock Repurchase Program of up to $50 Million Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that will drive t
XOMA Corporation has announced a stock repurchase program allowing for the purchase of up to $50 million of its common stock through January 2027. This initiative is part of the company's balanced capital allocation strategy, focusing on returning capital to shareholders while continuing to invest in growth opportunities. The management retains discretion on the timing and conditions for repurchases, which could vary based on market conditions and potential acquisitions. XOMA aims to leverage its royalty portfolio to enhance shareholder value significantly.
Read more →-XOMAO
Dec 19, 2023XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO Royalties Low-cost financing capitalizes on XOMA s $14 million acquisition of VABYSMO (faric
XOMA Corporation announced a non-dilutive, non-recourse loan worth up to $140 million from Blue Owl Capital, leveraging VABYSMO royalties. The funds will be used for stock repurchases and further acquisitions of royalties and milestones. This strategic financial move is expected to enhance XOMA's existing royalty portfolio, which includes marketed products and those in development. XOMA has already drawn $130 million, with the option for an additional $10 million depending on VABYSMO sales performance.
Read more →-XOMAO
Nov 7, 2023XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certa
XOMA Corporation reported its third quarter financial results for 2023, highlighting a revenue of $0.8 million, an increase from the previous year. The company secured $6.6 million from royalties and milestone payments and has filed one New Drug Application (NDA), with another anticipated before the end of the year. Additionally, XOMA plans to initiate multiple Phase 3 programs by year-end. However, the company also reported a higher net loss compared to the same quarter last year and announced the termination of a key licensing agreement.
Read more →-XOMAO
Aug 8, 2023XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-read
XOMA Corporation reported its second quarter 2023 financial results, highlighting the completion of two royalty acquisitions that add to its cash flow-generating assets. The company anticipates that at least one partner will file a New Drug Application in the third quarter of 2023. Despite a reported net loss of $5.4 million for the quarter, XOMA remains optimistic about potential revenue from its ongoing portfolio initiatives. However, they did record a one-time impairment charge related to a suspended collaboration with Bioasis, and lower milestone payments are expected in 2023.
Read more →-XOMAO
May 9, 2023XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy First quarter with incoming cashflows from two commercial assets Completed fir
XOMA Corporation reported its financial results for the first quarter of 2023, which included cash inflows from two commercial assets and the acquisition of a second cashflow-generating royalty asset. Although the company aims to accelerate its monetization strategy, it faced a significant increase in net losses, reporting $9.8 million for the quarter. Revenue also decreased sharply from $3.1 million in the previous year's first quarter to $0.4 million in Q1 2023. General and administrative expenses rose, reflecting higher costs in stock compensation and legal consultations.
Read more →-XOMAO
Mar 9, 2023XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy 2022 was the first year with cash receipts from a commercial asset since becoming
XOMA Corporation reported its full-year 2022 financial results, marking its first year with cash receipts from a commercial asset. The company noted its acquisition of the Ebopiprant royalty, which offers the potential for significant future earnings. Financial challenges were highlighted, with net losses reported, as well as rising administrative costs. However, anticipated cash flows from two commercial assets by 2024 suggest an optimistic outlook for future revenues.
Read more →-XOMAO
Nov 3, 2022XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related ma
XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
Read more →-XOMAO
Aug 4, 2022XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events The completion of Regeneron s acquisition of Checkmate Pharmaceuticals resulted in a $5 million milestone payment to Kuros, $2.5
XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events The completion of Regeneron s acquisition of Checkmate Pharmaceuticals resulted in a $5 million milestone payment to Kuros, $2.5 million of which was paid to XOMA in July. Data from Rez
Read more →-XOMAO
May 5, 2022XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with
XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with congenital hyperinsulinism in early 2022. Rezolute has an
Read more →-XOMAO
Mar 8, 2022XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events Earned $35 million milestone payment as NIS793 entered Phase 3 clinical study in metastatic pancreatic cancer Received $1.2 million f
XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events Earned $35 million milestone payment as NIS793 entered Phase 3 clinical study in metastatic pancreatic cancer Received $1.2 million from three milestone payments, two of which were from a si
Read more →-XOMAO
Nov 4, 2021XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events Added eight assets to its portfolio of potential milestone and royalty assets in 2021 NIS793 in combination with standard of care
XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events Added eight assets to its portfolio of potential milestone and royalty assets in 2021 NIS793 in combination with standard of care chemotherapy was granted Orphan Drug Designation for the
Read more →-XOMAO
Aug 5, 2021XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events Added six assets to its portfolio of potential milestone and royalty assets in 2021 Company earned $0.5 million milestone as Jan
XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events Added six assets to its portfolio of potential milestone and royalty assets in 2021 Company earned $0.5 million milestone as Janssen asset entered Phase 3 development NIS793 in combinat
Read more →-XOMAO
May 6, 2021XOMA Reports First Quarter 2021 Financial Results and Highlights Recent Operational Events XOMA s portfolio of potential milestone and royalty assets now has greater than 70 drug candidates. Company ended the first quart
XOMA Reports First Quarter 2021 Financial Results and Highlights Recent Operational Events XOMA s portfolio of potential milestone and royalty assets now has greater than 70 drug candidates. Company ended the first quarter of 2021 with $67.8 million in cash. The April 2021 $40
Read more →-XOMAO
Mar 10, 2021XOMA Reports Fourth Quarter and Full-Year 2020 Financial Results and Operating Highlights Recognized revenue of $29.4 million Six assets in the Company s milestone and royalty portfolio advanced to Phase 2 clinical devel
XOMA Reports Fourth Quarter and Full-Year 2020 Financial Results and Operating Highlights Recognized revenue of $29.4 million Six assets in the Company s milestone and royalty portfolio advanced to Phase 2 clinical development Completed $24.6 million Series A Perpetual Preferr
Read more →-XOMAO
Jan 5, 2021DISCLAIMERS Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including stateme
corporate PRESENTATION January 2021 NASDAQ: XOMA A Royalty Aggregation Company Exhibit 99.1 DISCLAIMERS Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exch
Read more →-XOMAO
Nov 5, 2020XOMA Highlights Recent Royalty Asset Portfolio Developments and Reports Third Quarter 2020 Financial Results Company recently earned a $25 million milestone payment as NIS793 advanced to Phase 2 development in advanced p
XOMA Highlights Recent Royalty Asset Portfolio Developments and Reports Third Quarter 2020 Financial Results Company recently earned a $25 million milestone payment as NIS793 advanced to Phase 2 development in advanced pancreatic cancer An undisclosed partner entered Phase 2 d
Read more →-XOMAO
Oct 28, 2020XOMA Earns $25 Million Milestone Payment as Anti-TGF Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic Cancer
XOMA Earns $25 Million Milestone Payment as Anti-TGF Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic Cancer EMERYVILLE, Calif., October 28, 2020 (GLOBE NEWSWIRE) XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGF monoclonal antibody licensed fro
Read more →-XOMAO
Aug 11, 2020CORPORATE PRESENTATION A ROYALTY AGGREGATION COMPANY AUGUST 2020 NASDAQ: XOMA 1 DISCLAIMERS Certain statements in this presentation are forward-looking Potential risks to XOMA meeting these expectations are statements wi
2020 NASDAQ: XOMA 1Exhibit 99.1 CORPORATE PRESENTATION A ROYALTY AGGREGATION COMPANY AUGUST 2020 NASDAQ: XOMA 1 DISCLAIMERS Certain statements in this presentation are forward-looking Potential risks to XOMA meeting these expectations are statements within the meaning of Sectio
Read more →-XOMAO
Aug 6, 2020XOMA Reports Second Quarter 2020 Financial Results Partners continue to advance clinical assets within the XOMA milestone and royalty portfolio, despite COVID-19-related clinical impacts
XOMA Reports Second Quarter 2020 Financial Results Partners continue to advance clinical assets within the XOMA milestone and royalty portfolio, despite COVID-19-related clinical impacts EMERYVILLE, Calif., August 6, 2020 (GLOBE NEWSWIRE) XOMA Corporation (Nasdaq: XOMA), today
Read more →-XOMAO
Dec 2, 2019FORM OF INSTRUCTIONS AS TO USE OF XOMA CORPORATION SUBSCRIPTION RIGHTS CERTIFICATES CONSULT THE INFORMATION AGENT, YOUR BANK OR YOUR BROKER AS TO ANY QUESTIONS The following instructions relate to a rights offering (the
FORM OF INSTRUCTIONS AS TO USE OF SUBSCRIPTION RIGHTS CERTIFICATES CONSULT THE INFORMATION AGENT, YOUR BANK OR YOUR BROKER AS TO ANY QUESTIONS The following instructions relate to a rights offering (the Rights Offering ) by XOMA Corporation, a Delaware corporation (the Company
Read more →-XOMAO
Nov 20, 2019XOMA Announces Proposed Rights Offering Rights Offering will be available to all shareholders of record on
XOMA Announces Proposed Rights Offering EMERYVILLE, Calif., November 19, 2019 (GLOBE NEWSWIRE) XOMA Corporation (Nasdaq: XOMA) ( XOMA or the Company ) today announced its intent to commence a rights offering pursuant to which the Company would raise approximately $22 million th
Read more →-XOMAO
Mar 7, 2019XOMA Reports Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights Added seven new partner-funded programs in 2018 with potential for milestone and royalty payments Current cash balance sufficient
XOMA Reports Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights Added seven new partner-funded programs in 2018 with potential for milestone and royalty payments Current cash balance sufficient to fund operations for multiple years EMERYVILLE, Calif.,
Read more →-XOMAO
Jan 7, 2019Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regardin
` corporate PRESENTATION January 2019 With over 35 years of discovery activity, XOMA currently has over three dozen partnered and fully-funded assets with the potential to drive milestone and royalty payments, along with multiple additional programs ready for out-licensing Exhib
Read more →-XOMAO
Nov 7, 2018XOMA Reports Third Quarter 2018 Financial Results
XOMA Reports Third Quarter 2018 Financial Results EMERYVILLE, Calif., November 7, 2018 (GLOBE NEWSWIRE) XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator, today announced its third quarter 2018 financial results. The third quarter of 2018 was exciting for XOM
Read more →-XOMAO
Sep 21, 2018XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte
XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte EMERYVILLE, Calif., September 21, 2018 (GLOBE NEWSWIRE) XOMA Corporation (NASDAQ: XOMA), announced today that for $15.0 million, it has acquired from Agenus (NASDAQ: AGEN) a
Read more →-XOMAO
Aug 14, 2018CORPORATE PRESENTATION WITH OVER 35 YEARS OF DISCOVERY ACTIVITY, XOMA CURRENTLY HAS OVER THREE DOZEN PARTNERED AND FULLY-FUNDED ASSETS WITH THE POTENTIAL TO DRIVE MILESTONE AND ROYALTY PAYMENTS, ALONG WITH MULTIPLE ADDIT
CORPORATE PRESENTATION WITH OVER 35 YEARS OF DISCOVERY ACTIVITY, XOMA CURRENTLY HAS OVER THREE DOZEN PARTNERED AND FULLY-FUNDED ASSETS WITH THE POTENTIAL TO DRIVE MILESTONE AND ROYALTY PAYMENTS, ALONG WITH MULTIPLE ADDITIONAL AUGUST 2018 PROGRAMS READY FOR OUT-LICENSING 1 FORWA
Read more →-XOMAO
May 9, 2018XOMA Reports First Quarter 2018 Financial Results Current cash balance sufficient to fund operations for multiple years
XOMA Reports First Quarter 2018 Financial Results Current cash balance sufficient to fund operations for multiple years EMERYVILLE, Calif., May 9, 2018 (GLOBE NEWSWIRE) XOMA Corporation (Nasdaq: XOMA), a pioneer in the discovery, development and licensing of therapeutic antibo
Read more →-XOMAO
Mar 7, 2018XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update Transformed business model to a royalty aggregator with extensive asset portfolio and capital; Added nine new partner-funded p
XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Transformed business model to a royalty aggregator with extensive asset portfolio and capital; Added nine new partner-funded programs in 2017 with potential for milestone and royalty payments; Curren
Read more →-XOMAO
Jan 8, 2018Forward-looking Statements Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in
Corporate Presentation (Nasdaq: XOMA) JANUARY 2018 Exhibit 99.1 Forward-looking Statements Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 193
Read more →-XOMAO
Nov 6, 2017XOMA Reports Third Quarter 2017 Financial Results Validated business strategy with transformational license agreements with Novartis; Expanded portfolio of partner-funded programs with potential for future milestone and
XOMA Reports Third Quarter 2017 Financial Results Validated business strategy with transformational license agreements with Novartis; Expanded portfolio of partner-funded programs with potential for future milestone and royalty payments; Current cash balance sufficient to fund
Read more →-XOMAO
Aug 8, 2017XOMA Reports Second Quarter 2017 Financial Results Executing new corporate strategy leveraging extensive portfolio of partnered programs Earned $10 million milestone payment from a pharmaceutical partner Reduced combined
XOMA Reports Second Quarter 2017 Financial Results Executing new corporate strategy leveraging extensive portfolio of partnered programs Earned $10 million milestone payment from a pharmaceutical partner Reduced combined R&D and G&A expenses 56% year-over-year Current cash ba
Read more →-XOMAO
May 9, 2017XOMA Reports First Quarter 2017 Financial Results Established new corporate strategy leveraging extensive portfolio of partnered programs Strengthened balance sheet with BVF Partners investment and substantial debt repay
XOMA Reports First Quarter 2017 Financial Results Established new corporate strategy leveraging extensive portfolio of partnered programs Strengthened balance sheet with BVF Partners investment and substantial debt repayment Reduced combined R&D and G&A expenses 49% year-over-
Read more →-XOMAO
Mar 16, 2017XOMA Reports Fourth Quarter and Full Year 2016 Financial Results Actions taken in 2016 set the stage for reduced operating costs and capital requirements In early 2017, Company established new strategic direction and val
XOMA Reports Fourth Quarter and Full Year 2016 Financial Results Actions taken in 2016 set the stage for reduced operating costs and capital requirements In early 2017, Company established new strategic direction and value drivers Berkeley, Calif., March 16, 2017 XOMA Corporat
Read more →-XOMAO
Mar 7, 2017Cowen & Company 37th Annual Health Care Conference (Nasdaq: XOMA)
Cowen & Company 37th Annual Health Care Conference (Nasdaq: XOMA) March 7, 2017 Exhibit 99.1 Cowen & Company 37th Annual Health Care Conference (Nasdaq: XOMA) March 7, 2017 Forward-looking Statements Certain statements in this presentation are forward-looking statements with
Read more →-XOMAO
Dec 21, 2016XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from Two License Agreements to HealthCare Royalty Partners and Provides Corporate Update Up to $22 million in revenue generated through sale of roya
XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from Two License Agreements to HealthCare Royalty Partners and Provides Corporate Update BERKELEY, Calif., December 21, 2016 (GLOBE NEWSWIRE) XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and d
Read more →-XOMAO
Dec 9, 2014XOMA Announces Pricing of $40.0 Million Registered Offering of Common Stock and Warrants
XOMA Announces Pricing of $40.0 Million Registered Offering of Common Stock and Warrants BERKELEY, Calif., December 9, 2014 XOMA Corporation (Nasdaq:XOMA), announced today the pricing of 8,097,165 shares of its common stock and accompanying warrants to purchase one share of com
Read more →-XOMAO
Mar 4, 2014XOMA Reports 2013 Operational Highlights and Fourth Quarter and Full-Year 2013 Financial Results
XOMA Reports 2013 Operational Highlights and Fourth Quarter and Full-Year 2013 Financial Results BERKELEY, Calif., March 4, 2014 -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced 2013 operational highlights an
Read more →-XOMAO
Nov 20, 2012XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial Berkeley, CA
XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial Berkeley, CA - November 20, 2012 -XOMA Corporation (Nasdaq: XOMA) today announced the 837-patient Phase 3 PATH trial (Perindopril Amlodipine for the Treatment of Hyperte
Read more →-XOMAO
Oct 3, 2012Company and Investor Contact: Ashleigh Barreto 510-204-7482 barreto@xoma.com Juliane Snowden The Oratorium Group, LLC jsnowden@oratoriumgroup.com Media Contact: Canale Communications Carolyn Hawley 619-849-5375
XOMA Announces Servier Has Initiated Phase 3 Gevokizumab Trial in Patients With Behcet's Uveitis BERKELEY, Calif., Sept. 27, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) today announced its partner, Servier has received authorization to initiate the Servier-sponsored
Read more →-XOMAO
Mar 6, 2012] XOMA Announces Pricing of $39.2 Million Public Offering of Common Stock and Warrants
XOMA Announces Pricing of $39.2 Million Public Offering of Common Stock and Warrants BERKELEY, Calif., March 6, 2012 - XOMA Corporation (NASDAQ: XOMA), announced today the pricing of 29,669,154 shares of its common stock and accompanying warrants to purchase one half of a share
Read more →-XOMAO
Jan 17, 2012] XOMA Acquires U.S. Rights to Perindopril Franchise and Establishes Commercial Operations Berkeley, CA
XOMA Acquires U.S. Rights to Perindopril Franchise and Establishes Commercial Operations Berkeley, CA - January 17, 2012 -XOMA Corporation (Nasdaq: XOMA) today announced it has acquired U.S. rights to the perindopril franchise from Les Laboratoires Servier, XOMA's partner for i
Read more →-XOMAO
Jan 5, 2012] XOMA Appoints John Varian as Chief Executive Officer Berkeley, CA
XOMA Appoints John Varian as Chief Executive Officer Berkeley, CA - January 5, 2012 - XOMA Corporation (Nasdaq: XOMA) today announced its Board of Directors has appointed John Varian as Chief Executive Officer. Mr. Varian has been serving as the Interim Chief Executive since Aug
Read more →-XOMAO
Jan 3, 2012] XOMA Secures $10 Million Term Loan
XOMA Secures $10 Million Term Loan BERKELEY, Calif., January 3, 2012 - XOMA Corporation (Nasdaq: XOMA), a leader in the discovery and development of antibody therapeutics, announced that it has entered into a $10.0 million 42-month secured term loan agreement with GE Capital, He
Read more →Competitive Position
How XOMAO ranks across every disease it competes inCompetitive Position is a premium feature
See how XOMAO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial